• Boadie W Dunlop.
• a Emory University School of Medicine , 12 Executive Park NE, 3rd Floor, Atlanta, GA 30329, USA.
• Expert Rev Clin Pharmacol. 2015 Jan 1; 8 (6): 669-72.

AbstractImproving the treatment of major depressive disorder will require identification of moderators that predict differential outcomes across treatments at the level of the individual patient, referred to as precision medicine. Currently, there are no biological measures demonstrated to enhance treatment selection accuracy although there are some clinical variables that have prognostic value. Several recent studies comparing treatments with differing mechanisms of action have identified potential moderators that may eventually be used in precision medicine approaches. Genetic combination tests, systemic inflammation, electroencephalography and neuroimaging, in particular, show significant potential for near-term development as clinically meaningful moderators for use in treatment selection. Ultimately, combinations of moderators may provide the greatest level of precision in selecting optimal treatment approaches for individual depressed patients.

24 keywords...

hide…